What is the present valuation and projected CAGR of the diabetic ketoacidosis (dka) market?
The diabetic ketoacidosis (DKA) market size has grown strongly in recent years. It will grow from $2.90 billion in 2024 to $3.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increased diabetes prevalence, delayed diagnosis of type 1 diabetes, insufficient insulin therapy adherence, increased obesity rates, and lack of diabetes education programs.
The diabetic ketoacidosis (DKA) market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to advancements in insulin delivery systems, increasing adoption of continuous glucose monitoring, growing awareness of diabetes complications, expansion of telemedicine for diabetes management, and rising healthcare expenditure. Major trends in the forecast period include the integration of artificial intelligence in diabetes care, the development of closed-loop insulin delivery systems, personalized medicine, advanced technologies, and innovative therapies.
Get Your Free Sample of The Global Diabetic Ketoacidosis (DKA) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21168&type=smp
What key drivers have fueled the diabetic ketoacidosis (dka) market’s development over the years?
The increasing prevalence of obesity is driving the expansion of the diabetic ketoacidosis (DKA) market. Obesity refers to a medical condition characterized by excessive body fat accumulation that can negatively impact health and increase the risk of various diseases. Obesity is rising due to a combination of factors, including unhealthy diets high in processed foods, sugars, and fats, sedentary lifestyles with reduced physical activity, increased screen time, and socioeconomic factors such as access to affordable healthy food and healthcare. Obesity rates increase the risk of diabetic ketoacidosis (DKA) by contributing to insulin resistance and the development of type 2 diabetes, which can lead to poor blood sugar control and subsequent DKA episodes. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the rising prevalence of obesity is driving the growth of the diabetic ketoacidosis market.
What is the segmentation for the diabetic ketoacidosis (dka) market?
The diabetic ketoacidosis (DKA) market covered in this report is segmented –
1) By Type: Pediatric Diabetic Ketoacidosis, Adult Diabetic Ketoacidosis
2) By Treatment Type: Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Intermediate-Acting Insulin, Long-Acting Insulin
3) By Route of Administration: Oral, Parenteral, Other
4) By Distribution Channel: Online Channel, Offline Channel
5) By End Use: Hospitals, Ambulatory Care Center, Specialty Clinics
Subsegments:
1) By Pediatric Diabetic Ketoacidosis: Mild Pediatric DKA, Moderate Pediatric DKA, Severe Pediatric DKA
2) By Adult Diabetic Ketoacidosis: Mild Adult DKA, Moderate Adult DKA, Severe Adult DKA
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/diabetic-ketoacidosis-dka-global-market-report
Who are the most influential companies in the diabetic ketoacidosis (dka) market?
Major companies operating in the diabetic ketoacidosis (DKA) market are Merck And Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited
What are the top industry trends projected to impact the diabetic ketoacidosis (dka) market?
Major companies operating in the diabetic ketoacidosis market are focusing on developing innovative technologies, such as continuous glucose monitor tools, to improve early detection, better manage blood glucose and ketone levels, and ultimately reduce the incidence and severity of DKA episodes in individuals with diabetes. Continuous glucose monitor (CGM) tools refer to devices that continuously track glucose levels in the body, providing real-time data to help individuals with diabetes manage their blood sugar levels. For instance, in June 2022, Abbott Laboratories, a US-based medical device company, launched novel continuous glucose-ketone monitoring systems to provide real-time tracking of both glucose and ketone levels. This system combines the tracking of both glucose and ketone levels in real-time, providing a comprehensive view of a patient’s metabolic state. By measuring both glucose and ketones, it allows for early detection of potential diabetic complications, such as diabetic ketoacidosis (DKA), before they become critical. The system is designed for continuous monitoring, offering users convenient and frequent data updates without the need for manual testing.
What are the major regional insights for the diabetic ketoacidosis (dka) market, and which region holds the top position?
North America was the largest region in the diabetic ketoacidosis (DKA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic ketoacidosis (DKA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Diabetic Ketoacidosis (DKA) Market Report 2025 Offer?
The diabetic ketoacidosis (dka) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Diabetic ketoacidosis (DKA) refers to a serious diabetes complication where the body produces high levels of blood acids called ketones, often due to insufficient insulin, leading to dehydration, electrolyte imbalances, and potentially life-threatening conditions. They are used for diagnosing and managing severe metabolic imbalances in diabetic patients to prevent complications such as dehydration, organ failure, and coma.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21168
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
